A phase I dose-finding study using an innovative sequential biweekly schedule of irinotecan followed 24 hours later by capecitabine Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Neoplasms

abstract

  • The suggested Phase II dose of this combination and schedule is irinotecan 100 mg/m(2) and capecitabine 1000 mg/m(2) BID. Some patients tolerated a capecitabine dose as high as 1250 mg/m(2) BID.

publication date

  • April 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1080/07357900701208915

PubMed ID

  • 17530484

Additional Document Info

start page

  • 148

end page

  • 53

volume

  • 25

number

  • 3